Altoida Raises $6.3M Series A to Predict Alzheimer's Disease Risk Using Artificial Intelligence, Machine Learning and Augmented Reality

Altoida Inc. today announced a $6.3 million round of venture capital financing to bring its FDA-cleared and CE Mark-approved medical device and brain health data platform to patients, physicians and researchers around the globe. Led by a team of esteemed neuroscientists, physicians and computer scientists, Altoida uses digital biomarkers to drive better clinical outcomes for brain disease. The Series A round was led by M Ventures, the corporate venture capital arm of the science and technology company Merck KGaA, Darmstadt, Germany, with participation from Grey Sky Venture Partners, VI Partners AG, Alpana Ventures, and FYRFLY Venture Partners. The new capital will be used to further expand Altoida's global presence with an immediate focus on commercialization activities in the US and EU markets. "Altoida is at the forefront of a new era to leverage Artificial Intelligence and Machine Learning to assess brain health," said Alexander Hoffmann, Principal, New Businesses at M Ventures.